Key Highlights

  • Shares of Lyell Immunopharma (NASDAQ:LYEL) reached USD 14.28 intraday on November 4, 2026, a gain of 32.59% or USD 3.51 over the prior session, on 166.58 thousand shares traded.
  • The firm agreed to issue 7,428,040 shares at USD 10.77, matching the November 3 closing level, for roughly USD 80 million before fees, and a release timed at 9:02 a.m. ET listed ARCH, Adage, Caligan and RTW as participants.
  • Funding is projected to carry operations into 2028, bridging to pivotal ronde-cel results in mid-2027 and a planned BLA filing during the second half of 2027.
  • A same-day release put the response rate at 91% and the complete response rate at 77% among 44 evaluable third-line patients, company-reported figures ahead of the December 2026 ASH meeting.

Intraday Price Action at Lyell Immunopharma (up USD 3.51, 32.59%)

Lyell Immunopharma (NASDAQ:LYEL) rose USD 3.51, or 32.59%, to USD 14.28 during trading on November 4, 2026. The November 3 close works out to about USD 10.77 (calculated), matching the Placement price. The 9:02 a.m. ET announcement described a private placement of 7,428,040 common shares for about USD 80 million before expenses, with closing expected on or about November 4, 2026. Goldman Sachs and Leerink Partners served as placement agents. Participants included ARCH Venture Partners, Adage Capital Management, Caligan Partners, RTW Investments and other institutions. Pricing at the prior close meant no discount.

Clinical Progress and Pipeline

In a separate company release on November 4, 2026, the firm presented refreshed data on ronde-cel, a CD19/CD20 CAR T cell therapy for large B-cell lymphoma, slated for the 68th ASH Annual Meeting from December 12 to 15, 2026. Among 58 third-line PiNACLE patients treated through the June 18, 2026 data cutoff, 44 could be assessed at Day 84, producing an overall response rate of 91% (40 of 44) and a complete response rate of 77% (34 of 44). Cytokine release syndrome at grade 3 or higher did not occur, while grade 3 or higher neurotoxicity appeared in 9%. These company-reported, single-arm figures are not independently verified. The pivotal dataset is anticipated in mid-2027, with a BLA submission in the second half of 2027.

Share Dilution, Capital and Risk

Issuing new stock brings in cash but divides ownership among a larger number of shares. Assuming the intraday market Capitalization of USD 349.93 million is accurate, it works out to about 24.5 million shares at USD 14.28, which would make the 7.43 million new shares roughly 30% more (simple arithmetic, not confirmed). These shares are unregistered and come with resale registration rights on Form S-3, so a later registration could introduce more supply. Proceeds are earmarked for the ronde-cel pivotal trials, LYL273 in colorectal cancer and working capital. Trading Volume of 166.58 thousand shares is light, so a handful of transactions can push the price around and quoted gains may reverse. The company still generates no revenue, and a BLA submission remains about two years away with no approval guaranteed.

Where Things Stand

Lyell Immunopharma (NASDAQ:LYEL) has climbed 32.59% as an USD 80 million placement at USD 10.77, drawn from specialist healthcare investors, landed alongside updated ronde-cel results showing a 91% response rate, and because the new cash pushes its runway into 2028. The results come from a company-reported single-arm group, and the added shares bring dilution. Upcoming checkpoints include the ASH presentations on December 12 and December 14, 2026, closing of the placement, the Form S-3 resale registration and the pivotal dataset due in mid-2027.